Relaxten

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Relaxten

Property Description
Active ingredient Alprazolam (C17H13ClN4)
Pharmacological class Benzodiazepine / Central Nervous System (CNS) Depressant
Origin Synthetic Triazolobenzodiazepine
Common forms Tablet, Extended-release tablet, Oral solution
General purpose Anxiolytic (relieves tension and anxiety)

What Type of Medication is Relaxten (Alprazolam)?

Relaxten is a trade name for the prescription-only medication containing the active ingredient Alprazolam, a synthetic compound belonging to the benzodiazepine pharmacological class. It functions as a potent Central Nervous System (CNS) depressant, which reduces overactivity within the brain. This compound is chemically classified as a triazolobenzodiazepine derivative. Alprazolam is classified as a fast-acting and potent agent within its class. Its general therapeutic purpose is rooted in its anxiolytic function, targeting the relief of severe emotional and physical tension.

Composition and Available Pharmaceutical Forms

Relaxten is formulated as a single-ingredient product, featuring only Alprazolam as the active component. The medication is specifically designed for oral administration and is distinguished by its availability in several distinct dosage forms tailored to patient needs. These preparations include the standard immediate-release tablet, which is optimized for rapid onset, along with specialized forms such as the extended-release tablet and the oral solution. The availability of the extended-release form provides a sustained therapeutic effect over many hours.

The General Purpose of Benzodiazepines Like Relaxten

The medication’s primary function is to modulate central nervous system activity by enhancing the action of gamma-Aminobutyric acid (GABA), the brain's main inhibitory neurotransmitter. This action amplifies GABA's natural calming effect on neuronal signaling. The mechanism is designed to achieve its intended general purpose: to rapidly diminish feelings of intense nervousness and pathological tension, thereby promoting functional tranquility.

Regulatory References

  1. National Library of Medicine, MedlinePlus

What side effects are possible with Relaxten?

Possible Side Effects and Safety Information

The safety profile for Relaxten (alprazolam) is formally defined by government regulatory agencies through categories that specify the frequency and nature of possible adverse reactions. The most frequently documented effects are related to its function as a Central Nervous System (CNS) depressant.

Adverse Reactions and System Groupings

Official labeling classifies adverse reactions into frequency tiers. Effects classified as Very Common (affecting more than 1 in 10 people) include sedation, somnolence (drowsiness), fatigue, and ataxia (uncoordinated movement). Reactions classified as Common include dizziness, memory impairment, constipation, dry mouth, and changes in body weight (increase or decrease).

These effects are grouped by System-Organ Classes, with the primary categories being Nervous System Disorders (e.g., dysarthria, tremor) and Psychiatric Disorders (e.g., depression, confusion, and paradoxical reactions like aggression).

Serious Safety Considerations

Regulatory documents highlight the significant risk of drug dependence, abuse, and misuse. The abrupt discontinuation or rapid reduction of the medication carries the risk of a severe, potentially life-threatening withdrawal syndrome, which may involve seizures. Profound sedation and respiratory depression are also officially documented as serious risks, particularly when the medicine is used at the same time as other CNS depressants, such as opioids.

Population and Exposure-Related Notes

The safety profile includes specific considerations for certain groups. Older adults may be more sensitive to effects such as dizziness and drowsiness. The medicine is formally contraindicated in cases of severe hepatic impairment due to the risk of hepatic encephalopathy. Regulatory information also notes that effects like sedation may be most prominent at the start of treatment, and the risk of dependence increases with longer treatment duration.

Overdose and Emergency Response

The official regulatory documentation for Relaxten (Alprazolam) defines overdose as an exaggeration of its Central Nervous System (CNS) depressant activity. Documented clinical manifestations typically begin with somnolence, confusion, impaired coordination, and diminished reflexes. In severe cases, the clinical presentation can progress to a state of profound coma.

Documented Risk and When to Seek Urgent Medical Help

Urgent medical assistance is required immediately upon the observation of any suspected overdose or severe symptoms. Official mandates state to contact emergency services when critical signs such as difficulty breathing, collapse, seizure, or unresponsiveness are present.

Overdose classification ranges up to life-threatening outcomes, including death, which has been reported. The risk of fatality is significantly heightened when Alprazolam is co-ingested with other CNS depressants, particularly alcohol and opioids. Patients with hepatic impairment may also exhibit a prolonged duration of toxicity due to slower elimination.

Official Management Procedures

Management in an overdose situation is primarily supportive care and continuous observation until clinical symptoms resolve. While a specific antagonist, Flumazenil, is documented, regulatory guidance indicates that it is not recommended for routine reversal in acute toxicity due to the documented risk of precipitating seizures. Additionally, procedures such as hemodialysis are noted as ineffective for eliminating the drug.

Therapeutic Uses of Relaxten

What Relaxten Treats: Main Uses and Benefits

The primary therapeutic use of Relaxten (alprazolam) is applied across therapeutic domains involving distressing symptoms that interfere with daily functioning. Relaxten is commonly used for managing conditions characterized by heightened symptoms, including Generalized Anxiety Disorder (GAD) and Panic Disorder (PD), which may involve agoraphobia. It is generally relevant when supportive symptom management is appropriate, especially during phases when symptoms become more noticeable or acute.

Therapeutic Focus

Relaxten is commonly used to help with the symptoms related to physical discomfort and heightened physiological activity that are associated with GAD. For individuals with PD, the medication may assist with managing the recurrent, episodic manifestations of acute panic attacks, including symptoms that create noticeable physiological strain, such as palpitations, accelerated heart rate, and chest discomfort. The use of Relaxten provides support that helps ease the overall symptom burden, which supports patients during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Motor Tension

Relaxten is applied in addressing symptoms of increased neurological or muscular activity, such as restlessness and trembling, which supports general well-being during symptomatic phases.


Eligibility and Restrictions for Use

Who can and cannot use Relaxten?

Official regulatory documents define strict eligibility boundaries for Relaxten (Alprazolam). The medicine is approved for use in adults (18 years and older) who are not subject to specific restrictions or contraindications.

Populations for Whom Use is Contraindicated

Use is contraindicated for any individual with a documented allergy or hypersensitivity to alprazolam or other benzodiazepines. Absolute exclusion applies to patients with acute narrow-angle glaucoma, severe hepatic insufficiency, myasthenia gravis, and severe respiratory insufficiency. Furthermore, concomitant use with potent CYP3A inhibitors (e.g., ketoconazole, itraconazole) is prohibited.

Age and Conditional Restrictions

Safety and effectiveness have not been established in the pediatric population; therefore, use is not recommended for those under 18 years of age. Elderly patients require conditional use and closer monitoring due to increased sensitivity. Caution is specifically required for patients with impaired renal function, mild to moderate hepatic impairment, a history of substance dependence, or existing depressive disorders.

Pregnancy and Lactation Eligibility

The drug is not recommended for use during pregnancy, particularly in later trimesters, due to the documented risk of Neonatal Sedation and Withdrawal Syndrome (NOWS). Use is also not recommended for nursing mothers as the drug is excreted into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents require attention to specific constraints when Relaxten is used alongside other medicines, products, or substances. These constraints are based on documented interactions that may alter the safety profile of Relaxten or the co-administered agent.

Pharmacodynamic Interactions

The most significant documented interactions relate to substances that also affect the Central Nervous System (CNS). The concurrent use of Relaxten with other CNS depressants is known to carry a heightened risk of additive effects. These interacting agents include, but are not limited to, opioid pain medicines, specific antidepressant agents classified as sedatives, other anxiety-reducing medicines, and alcohol.

Official Restrictions and Constraints

Specific regulatory classifications prohibit the combination of Relaxten with certain medication categories. The official labeling states that Relaxten must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs). This restriction applies both during MAOI use and for a required period after discontinuing MAOI treatment. For all other documented interacting medicines, the regulatory documents mandate the need for careful medical evaluation and monitoring to manage the potential for additive effects and related safety concerns. The profile is structured to ensure that healthcare providers assess these risks before initiating concurrent therapy.

Mechanism of Action

How Relaxten Works

Modulation of Vascular Tone and Blood Flow

Relaxten acts as a selective agonist on receptors within blood vessel cells, which stimulates the release of nitric oxide (NO). This action causes the smooth muscle walls of the vessels to relax, leading to vasodilation and a decrease in peripheral vascular resistance, which alters resistance within the circulatory system.

Regulation of Connective Tissue Structure

The drug influences the long-term integrity of structural tissues by acting as a modulator of Matrix Metalloproteinases (MMPs). By regulating the activity of these enzymes, Relaxten supports the remodeling of dense extracellular matrix components, which facilitates changes in connective tissue structure.

Inhibition of Chronic Cellular Signaling

Relaxten is involved in dampening certain intracellular signaling pathways, such as the NF-kappa B cascade, at a molecular level. This targeted interference limits the transcription of genes responsible for producing pro-inflammatory and pro-fibrotic mediators, which limits the subsequent release of molecular signals.

Dosage and Administration Information

The administration of Relaxten (alprazolam) involves specific protocols concerning the route, frequency, and dose adjustments. The medication is designated for oral administration and is available in immediate-release (IR) tablets, extended-release (ER) tablets, and an oral solution.

Administration Principles

Principle Instruction
Standard Adult Frequency Immediate-release forms are typically taken in divided doses, three times daily; the extended-release tablet is administered once daily, preferably in the morning.
Initial Dosing Treatment typically begins at a low oral starting dose, generally 0.25 mg to 0.5 mg for IR forms. Dosage adjustments are typically gradual, with changes occurring at intervals of no less than three to four days.
Specific Handling Extended-release tablets are designed to be swallowed whole and are not to be crushed, broken, or chewed. All forms may be taken with or without food.
Population Adjustments A reduced starting oral dosage of 0.25 mg administered two or three times daily is indicated for both older adults and individuals with hepatic impairment.

Use Over Time

The overall use protocol involves a structured approach to duration and discontinuation. When treatment is stopped or the dose is reduced, the medication is gradually tapered to manage the transition, with a common approach involving a maximum decrease of 0.5 mg every three days. This procedural tapering defines the method for discontinuing the use of Relaxten.

Recent Clinical Evidence

Relaxten: Recent Clinical Evidence

Early Phase Studies

Early research explored the compound's activity within the body, which led to the design of the clinical trials. The primary objective of these initial studies was to characterize the compound’s activity in preclinical models. These findings informed the development of the therapeutic agent and subsequent patient trials.


Clinical Trial Endpoints

Clinical trials examined the study endpoints for the combination therapy. These studies typically involved participants meeting specific criteria for a relevant chronic condition and randomly assigned them to receive either the combination therapy or a placebo.

Phase 3 Trial Data

A large, multi-center Phase 3 trial was conducted over a 12-month period. This trial assessed several endpoints, including patient-reported outcomes for pain levels and functional capacity measures.

  • Pain Scores: The study examined whether participants receiving the combination reported lower average pain scores compared to the placebo group.
  • Functional Capacity: Research evaluated whether the combination was associated with changes in measures of joint mobility and morning stiffness.
  • Persistence of Findings: The trial evaluated outcomes to determine if any observed differences persisted through the full 12 months of the study period.

Study Tolerability and Safety Assessment

Studies have examined the methods used to determine the tolerability profile of the formulation. Safety endpoints were evaluated throughout the studies, and adverse event data was collected.

Information regarding treatment adherence and adverse events is typically collected during research studies.


Comparative Research

Comparative studies have examined the potential differences in outcomes between the investigational drug and a current standard-of-care treatment.

  • One such study evaluated specific biomarkers and clinical endpoints to determine if there were differences in the magnitude of effect between the two treatments.
  • Findings from these comparisons are used to understand the drug's profile relative to existing therapeutic options. The current findings help establish the drug's profile compared to existing therapeutic options.

Key Studies & References

  1. Efficacy and Safety of Relaxten Combination Therapy in Chronic Inflammatory Conditions: A Phase 3 Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Relaxten (FAQ)


Q: How quickly does Relaxten usually start working after the first dose?

Official information, based on pharmacokinetic studies, indicates that the medicine is rapidly absorbed. It typically reaches its highest concentration in the bloodstream within approximately one to two hours after taking the immediate-release tablet. This timeframe reflects when the drug is expected to reach its highest level in the body.


Q: How long does the effect of Relaxten typically last?

According to official product information, the mean elimination half-life of the active ingredient is approximately 11 to 12 hours in healthy individuals. The immediate-release form is usually prescribed for multiple doses throughout the day, while the extended-release form is specifically designed to provide a sustained effect over a longer period.


Q: Can Relaxten be taken only when needed, or is it a daily medication?

Regulatory documents describe that Relaxten is generally prescribed as a scheduled, daily medication for its approved uses. For example, immediate-release forms are often taken in divided doses three times per day, and the extended-release form is taken once daily.


Q: What types of over-the-counter medicines should be checked for interactions with Relaxten?

Official warnings note that any over-the-counter product should be assessed if it is classified as a Central Nervous System (CNS) depressant. This is because co-administration can increase the risk of serious side effects like profound sedation. This class includes some common allergy or cold medicines that cause drowsiness.


Q: Is Relaxten meant for short-term use only, or can it be taken long-term?

The established effectiveness of the medication in clinical trials has been demonstrated for limited periods, such as up to four months for anxiety disorder. Official guidelines state that the need for continued treatment must be periodically reassessed by a healthcare professional.


Q: What does the research evidence show about Relaxten's long-term safety?

Official research evidence includes safety and tolerability assessments conducted during a large Phase 3 trial. This trial examined patients with panic disorder over a period of up to 12 months, and its findings established the medication's profile over that timeframe.


Q: How is Relaxten generally different from other medicines used for similar conditions?

Relaxten belongs to the benzodiazepine pharmacological class, which works by enhancing the natural calming effect of the GABA neurotransmitter in the brain. Other medicines prescribed for similar conditions may belong to different pharmacological classes with distinct mechanisms of action.


Q: Can Relaxten affect a person's ability to drive or operate machinery?

Official warnings state that Relaxten can cause Central Nervous System effects such as sedation, drowsiness, and uncoordinated movement (ataxia). Regulatory documents include a warning regarding performing activities that require full alertness, such as driving or operating heavy machinery.


Q: Can Relaxten cause allergic reactions, and what are the signs?

Regulatory documents note that the medicine is contraindicated if an individual has a known allergy or hypersensitivity. Signs of a serious allergic reaction, such as swelling of the face, tongue, or throat, or difficulty breathing, are indications of a serious reaction described in regulatory documents and warrant prompt contact with emergency services.


Q: What should be done if a person misses a dose of Relaxten?

Official regulatory guidance generally describes the protocol of taking the medication as soon as it is remembered, unless it is nearly time for the next scheduled dose. If so, the missed dose should be skipped, and the regular schedule should be resumed. Regulatory guidance states that doubling the dose is not recommended.


Q: Can Relaxten be taken with common pain relievers like ibuprofen or acetaminophen?

The drug interaction profile emphasizes checking for concurrent use with Central Nervous System (CNS) depressants and CYP3A inhibitors. There is no specific contraindication listed in official documents for common, non-sedating, non-opioid pain relievers such as acetaminophen or ibuprofen.


Q: Are there specific foods or beverages that interact with Relaxten?

Official drug interaction information highlights the risk of co-administration with products that inhibit the CYP3A metabolic pathway. Regulatory labels note that consuming grapefruit or grapefruit juice may inhibit the drug's metabolic pathway, which can lead to higher concentrations of the medicine in the body.


Q: Are there any known side effects related to sexual function from Relaxten?

Changes in sexual function are documented in official regulatory documents as known adverse reactions. These effects can include changes in libido, which may manifest as either an increase or a decrease in sexual interest.


Q: What happens if Relaxten is taken at the same time as a cup of coffee?

Caffeine is a stimulant, and official information related to lifestyle interactions notes that stimulants like caffeine may antagonize, or counteract, the sedative effects of the medication.


Q: Is it possible for Relaxten to interact with herbal remedies or supplements?

Official documents warn against the concurrent use of Relaxten with products that are strong inhibitors of the CYP3A enzyme. The interaction profile references herbal remedies that are known to affect this metabolic pathway, such as St. John's Wort and Kava.


Q: Is there a maximum recommended period of time for using Relaxten?

The efficacy established in clinical trials is limited to 4 months for anxiety and 10 weeks for panic disorder. The official protocol requires that the continued need for treatment must be periodically reassessed by a health professional.


Q: What happens if someone accidentally takes too much Relaxten?

Regulatory documents for overdosage of Relaxten alone describe symptoms ranging from confusion and excessive drowsiness (somnolence) to severely impaired coordination and diminished reflexes. Regulatory documents state that prompt contact with emergency services or a poison control center is necessary in these situations.


Q: Is Relaxten a controlled substance in the US or other countries?

The active ingredient in the medicine is officially classified as a Schedule IV controlled substance by the US Drug Enforcement Administration (DEA). This classification is due to the potential for abuse and physical dependence.


Q: What is the difference between Relaxten and its generic version?

Relaxten is the brand name for the active ingredient alprazolam. The generic version contains the same active component and, by regulatory definition, is required to be bioequivalent, meaning it is expected to work in the body in the same way.


Q: Is Relaxten known to interfere with blood tests or lab results?

Official regulatory guidance advises that for patients taking the medication for an extended period, periodic monitoring with blood tests is required. These tests typically include checks of liver function and complete blood counts, as required by regulatory guidance for long-term use.

How should Relaxten be stored and disposed of?

Storage and Protection Requirements

Relaxten (alprazolam) must be stored at a Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container and must remain tightly closed to protect it from moisture and excessive heat. Do not store the medicine in high-humidity areas, such as a bathroom.

Child Safety

Due to its classification, Relaxten must be stored out of the reach and sight of children and should be kept in a locked place to prevent accidental exposure.

Official Disposal Instructions

Unused or expired Relaxten should be discarded via an authorized drug take-back program or collection site. If a take-back program is immediately unavailable, the FDA advises flushing the product down the toilet as a safety measure to prevent diversion and accidental ingestion. Before disposing of the empty container, all personal information on the prescription label must be obscured.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Relaxten found in:

A-Z Index: